Ioversol is an organoiodine compound, which contains one or more carbon-iodine bonds. It is a radiopaque contrast agent that absorbs X-rays. It allows blood vessels, organs, and other non-bony tissues to be seen more clearly on a CT scan or other radiologic (X-ray) examination. This unique property of ioversol has led to increased application such as in ultrasound scattering and magnetic resonance imaging. It helps to diagnose disorders of the heart, brain, and blood vessels.

Rise in number of accidents and increase in prevalence of bone-related diseases & kidney problems are the key drivers of the global ioversol market. In addition, growth in geriatric population has led to increased orthopedic disorders and cardiovascular disorders, resulting in the development of the X-ray industry, which in turn fuels the market growth. However, overdose of ioversol might lead allergic reaction; breathing problem; swelling of the face, lips, tongue, or throat; and dehydration & dry skin, which restrains the market growth. Increase in spending on healthcare and advancements in X-ray, CT scan, and other radiological & diagnostic examinations are anticipated to provide new opportunities for the market players.

The global Ioversol market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Ioversol volume and value at global level, regional level and company level. From a global perspective, this report represents overall Ioversol market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Ioversol in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Ioversol manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Liebel-Flarsheim Company LLC
Guerbet
Jiangsu Hengrui Medicine Co
Mallinckrodt Pharmaceuticals
Ultraject
China Resources Pharmaceutical (Shanghai) Co
HB Ocean
Novalek Pharmaceuticals Pvt. Ltd
Stellence Pharmscience Pvt. Ltd
A.S. Joshi & Company

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Ioversol 34% Injectable Solution (Optiray 160)
Ioversol 51% Injectable Solution (Optiray 240)
Ioversol 64% Injectable Solution (Optiray 300)
Ioversol 68% Injectable Solution (Optiray 320)
Ioversol 74% Injectable Solution (Optiray 350)

Segment by Application
X-ray
CT Scan
Brain Disorders
Blood Vessel Disorders
Heart Disorders
Others